Saturday, July 11, 2026

biotech · Locally Advanced Breast Cancer (LABC) · Mantle Cell Lymphoma

Beijing Luzhu Biopharmaceutical

Beijing Luzhu Biopharmaceutical clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Beijing, CN HQ
2 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Beijing, CN
Employees
2
Programs
7
Drugs
5
Patents
0
Intelligence · Clinical Programs

Beijing Luzhu Biopharmaceutical projects

2 ClinicalTrials.gov programs sponsored by Beijing Luzhu Biopharmaceutical.

Beijing Luzhu Biopharmaceutical has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ICP-022

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial
  2. ICP-022

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Beijing Luzhu Biopharmaceutical have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.